Tandem Diabetes Care

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tandem Diabetes Care reports robust sales growth and strategic innovations

Tandem Diabetes Care's strong financial performance, innovative product portfolio, and global market expansion efforts position it for continued growth and competitiveness.
While facing short-term challenges like seasonal EBITDA fluctuations and acquisition-related headwinds, Tandem's strategic focus on new product launches and market awareness presents opportunities for long-term success.
The company's emphasis on technology advancements, clinical initiatives, and leadership continuity underscores its commitment to driving innovation and meeting customer needs in the insulin therapy market.
With a clear roadmap for 2023, including revenue projections, margin expectations, and product development plans, Tandem is poised to navigate challenges and capitalize on growth opportunities in the evolving healthcare landscape.

Tandem Diabetes Care reports strong Q1 performance amidst competitive challenges

Tandem Diabetes Care's Q1 2023 earnings call showcased strong performance driven by product success and customer loyalty, despite challenges in international revenue and competitive landscape noise.
The company's focus on innovation, cost management, and product enhancements positions it well for long-term growth and market expansion, with opportunities in Libre integration and upcoming product launches.
While facing short-term challenges in Q2 revenue and margins, Tandem Diabetes Care remains confident in achieving its objectives through prudent cost management and commitment to product excellence.

Tandem Diabetes Care exceeds Q2 targets, eyes sustainable growth

Tandem Diabetes Care (TNDM) showcased strong Q2 performance, with a focus on sustainable growth and profitability. While facing challenges like market uncertainties, the company is leveraging opportunities through new product launches and cost efficiencies for future growth.

Tandem Diabetes Care surpasses Q3 sales expectations amidst market challenges

Tandem Diabetes Care's Q3 performance exceeded expectations with strong sales and positive margins, despite challenges in OUS distribution.
The company's focus on innovation, product success, and market positioning sets the stage for future growth opportunities.
Navigating disruptions and seizing growth potential through new product launches and market expansion are key priorities for Tandem.
Overall, Tandem remains optimistic about its trajectory and is actively pursuing strategic opportunities for growth.

Tandem Diabetes Care reports strong sales growth and strategic focus

Tandem Diabetes Care's Q4 2023 Earnings Call highlighted strong sales performance, positive customer feedback, and strategic focus on new product launches and operational efficiencies.
While facing challenges from unique events and increasing competition, Tandem is leveraging opportunities in U.S. and international markets, focusing on growth and innovation.
The company's outlook for 2024 includes a robust sales guidance, expansion plans, and a strategic approach to address market challenges and capitalize on emerging opportunities.

Tandem Diabetes Care reports robust Q1 sales growth and international expansion

Tandem Diabetes Care's Q1 2024 earnings call highlighted strong sales growth, successful product launches, and innovation in AID systems, with a focus on maintaining pricing and expanding internationally.
Challenges include pricing strategies, monitoring Mobi's impact, and navigating competitive OUS markets, while opportunities lie in market expansion, health outcome studies validation, and improving access and affordability.
Overall, Tandem's performance reflects a strategic approach to growth through product innovation, market expansion, and a focus on enhancing access and affordability in the diabetes care market.

Tandem Diabetes Care (TNDM) posts strong Q2 results, raises 2024 guidance

Tandem Diabetes Care (TNDM) reported robust Q2 2024 performance with sales growth, improved gross margin, and raised sales guidance. The company's focus on new products and commercial excellence positions it well for future growth.

Tandem Diabetes Care achieves record sales and positive cash flow

Tandem Diabetes Care delivered a strong performance in Q3 2024, marked by record sales and positive free cash flow. The company's focus on innovation, market awareness, and customer retention are key strengths. While facing challenges in a competitive market, Tandem Diabetes Care is well-positioned to capitalize on growth opportunities in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2023 results after the financial markets close on Thursday, August 3, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2023 financial and operating results. A live webcast of the call will be available on Tandem Diab.

Tandem Diabetes Care to Announce Second Quarter 2023 Financial Results on August 3, 2023

Golar LNG

Penn Entertainment

Primo Water

iStar Inc

SunPower

Xencor

Battered stocks to buy usually represent the exclusive avenue of the extreme speculator. As many beginner investors often find out, you don't want to take the buy low, sell high adage blindly without conducting serious due diligence.

7 Battered Stocks That Could TRIPLE by 2024

Tandem Diabetes Care experienced a Q1 2023 financial downturn, yet expects a 10%-12% annual growth rate. Despite weak recent stock performance, Tandem exhibits a robust growth profile but faces profitability challenges. With plans for international expansion and new product launches, a cautious 'Hold' is recommended for investors.

Tandem Diabetes Care: Navigating Through Rough Seas

Dollar Tree

Five Below

Sempra Energy

Advance Auto Parts

Chicago Rivet & Machine

Progressive

Ordinarily, a blisteringly hot jobs report wouldn't inspire discussions about stocks to buy before crash. Essentially, the latest employment readout suggested that more money chases after fewer goods.

7 Names to Buy as Stock Market Crash Fears Fester

Novo Nordisk

Novo Nordisk's expertise in diabetes care is about to produce another promising medicine. Tandem Diabetes Care is looking to take advantage of the vast insulin-pump opportunity.

Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond.

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 1:30pm Eastern Time (10:30am Pacific Time). The Company update presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care'.

Tandem Diabetes Care to Present at the Jefferies Healthcare Conference

According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.

Tandem Diabetes (TNDM) Q1 Earnings Miss, Gross Margin Dips

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Susan Morrison - Executive Vice President and Chief Administrative Officer John Sheridan - President and Chief Executive Officer Brian Hansen - Executive Vice President and Chief Commercial Officer Leigh Vosseller - Executive Vice President and Chief Financial Officer Conference Call Participants Matthew Miksic - Barclays Steven Lichtman - Oppenheimer Christopher Pasquale - Nephron Research Brooks O'Neil - Lake Street Capital Markets Nathan Treybeck - Wells Fargo Securities Danielle Antalffy - UBS Matthew Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Joanne Wuensch - Citi Research Matthew Blackman - Stifel Joshua Jennings - TD Cowen Stephanie Piazzola - Bank of America Securities Alexander Nowak - Craig-Hallum Michael Polark - Wolfe Research Operator Good day and thank you for standing by. Welcome to Tandem Diabetes Care First Quarter 2023 Earnings Conference Call.

Tandem Diabetes Care, Inc. (TNDM) Q1 2023 Earnings Call Transcript

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.23 per share a year ago.

Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Lags Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2023 and reaffirmed its financial guidance for the year ending December 31, 2023. First Quarter Highlights Worldwide installed base increased 22 percent to approximately 430,000 in-warranty customers compared to the first quarter 2022. Publication in the New England Journal of Medicine of study demo.

Tandem Diabetes Care Announces First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Guidance

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 4:40pm Eastern Time (1:40pm Pacific Time). The Company update presentation will be webcast live, and an archive recording will be available for 30 days.

Tandem Diabetes Care to Present at the BofA Securities 2023 Health Care Conference

Axsome Therapeutics

Axsome is expecting important developments that should improve its already-bright prospects. Tandem's innovative insulin pump should allow it to capture a larger share of the diabetes market.

2 Beaten-Down Growth Stocks to Buy in April

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by Diabetes Technology & Therapeutics of a meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology.

Tandem Diabetes Care Announces Control-IQ Technology Meta-analysis Demonstrating Positive Clinical Impact of Automatic Correction Bolusing on Glucose Control in People with Type 1 Diabetes

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2023 results after the financial markets close on Wednesday, May 3, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2023 financial and operating results.

Tandem Diabetes Care to Announce First Quarter 2023 Financial Results on May 3, 2023

Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.

Tandem Diabetes (TNDM) Gains on Pump Sales, Margin Woe Stays

Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.

Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc.

Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with Control-IQ Technology

Tandem Diabetes Care is having issues on the top and bottom lines. However, the medical device maker still boasts plenty of growth avenues.

This Stock Could Soar By as Much as 106%, According to Wall Street

Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.

Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - President, CEO & Director Leigh Vosseller - EVP, CFO & Treasurer Conference Call Participants Matt Miksic - Barclays Brooks O'Neil - Lake Street Capital Partners Chris Pasquale - Nephron Research Steve Litchman - Oppenheimer Alex Nowak - Craig-Hallum Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Joanne Wuensch - Citi Travis Steed - Bank of America Nathan Treybeck - Wells Fargo Jeff Johnson - Baird Matthew Blackman - Stifel Joshua Jennings - Cowen Operator Good day, and welcome to the Tandem Diabetes Care Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Tandem Diabetes Care, Inc. (TNDM) Q4 2022 Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rebecca Robertson as Chair of its Board of Directors. Ms. Robertson, who joined Tandem's Board as an independent director in January 2019, succeeds Kim Blickenstaff, who will continue as a member of the Board.

Tandem Diabetes Care Appoints New Chair of Board of Directors

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #ControlIQ--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2022 and provided its financial guidance for the year ending December 31, 2023. 2022 Financial Highlights In comparing the year ended December 31, 2022 to the same period of 2021: Worldwide installed base increased 29 percent to approximately 420,000 customers.

Tandem Diabetes Care Announces Fourth Quarter 2022 Financial Results and Full Year 2023 Financial Guidance

Fiverr

Don't wait too long before loading up on these stocks.

2 Growth Stocks to Buy While They Are Still Down

SAN DIEGO--( BUSINESS WIRE )--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced the completion of its previously announced acquisition of AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump. The Sigi Patch Pump, designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges, is under development and not commercially available.

Tandem Diabetes Care Completes Acquisition of Insulin Patch Pump Developer, AMF Medical

SAN DIEGO--( BUSINESS WIRE )--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2022 results after the financial markets close on Wednesday, February 22, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2022 financial and operating results.

News for Tandem Diabetes Care Stock (TNDM)